CV Lattes
Universidade Estadual Paulista (UNESP). Campus de Araraquara. Faculdade de Ciências Farmacêuticas (FCFAR) (Institutional affiliation from the last research proposal) Birthplace: Brazil
graduate at Farmácia Bioquímica from Universidade Federal do Paraná (1975), master's at Science and Technology of the Food from Universidade Estadual de Campinas (1978) and ph.d. at Science and Technology of the Food from Universidade Estadual de Campinas (1984). Has experience in Microbiology, focusing on Medical Microbiology, acting on the following subjects: mycobacterium tuberculosis, tuberculose, maba, m tuberculosis and pcr. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
This project aims to understand more about TB that affects diverse populations surrounding of São Paulo (São Paulo, Araraquara) and Mato Grosso do Sul (indigenous and non-indigenous) states, evaluated patients with pulmonary tuberculosis treated in their respective Arnbulatories and Health Services. It will be performed: 1) sputum baciloscopy; 2) Mycobacteria isolation through CULTIVO (BA…
The Mycobacterium tuberculosis, the major agent of tuberculosis (TB), is responsible for approximately 2-3 million people annually death, with a global economic injury of ~$12 billion per year. It is estimated that 1/3 of the worldwide population are infected with the latent form bacilli. Although, no new specific drug against the M. tuberculosis was developed since 1960. It is expected t…
(Only some records are available in English at this moment)
Mycobacterium tuberculosis (MTB), agent of tuberculosis (TB), is responsible for the death of around 2-3 million people annually and a global economic toll of ~$12 billion each year. No new specific drug against (MTB) has been developed since 1960 and the emergence of MDR-TB and XDR-TB highlight the ineffectiveness of current treatment. It is hoped that the new drug against TB could: (i) …
Mycobacterium tuberculosis, the major agent of tuberculosis (TB), is responsible for approximately 2-3 million people annually death, with a global economic injury of ~$12 billion per year. It is estimated that 1/3 of the worldwide population are infected with the latent form bacilli. Although, no new specific drug against the M. tuberculosis was developed since 1960. It is expected that …
| 14 / 8 | Completed research grants |
| 8 / 3 | Completed scholarships in Brazil |
| 22 / 11 | All research grants and scholarships |
| Associated processes | |